Medidur FAME enrolment passes half way mark
Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.
Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.
FAME is a double-masked, randomized, multicentre study that will follow around 900 patients across the US, Canada, Europe and India for 36 months, studying the efficacy and safety of Medidur.
Medidur is an injectable intravitreal insert that is designed to deliver low doses of fluocinolone acetonide to the retina over a period of up to three years, as a treatment for diabetic macular oedema (DME). Using a proprietary 25-gauge transconjunctival injector system, Medidur is inserted into the vitreous during an outpatient procedure.
